Interstitial lung disease in lung cancer: separating disease progression from treatment effects.
about
Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis.Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patientsLessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures.Drug induced interstitial lung disease.Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care.Erlotinib in non-small cell lung cancer: a review.Perspectives on novel therapies for bronchial carcinoma.Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trialPulmonary toxicity from novel antineoplastic agents.Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer: A case report.Progressive multiple cystic changes in both lungs in a patient treated with gefitinib for lung adenocarcinoma with multiple lung metastases.Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.Gefitinib-induced interstitial pneumonia: A case report and review of the literature.Exploring differences in drug doses between Japan and Western countries.A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.Pulmonary toxicities from targeted therapies: a review.Safety of palliative chemotherapy in advanced pancreatic cancer.Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilationInterstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2.Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer.Bleomycin-Induced Lung Injury
P2860
Q30540860-BFBF360E-5CE9-4403-A4CB-FAD2514E99ABQ31026775-187F7232-8E2F-4675-8AEE-C016CC94C663Q34138798-60EF4ADB-F4A7-43A3-8AE4-A05D8F68DF24Q34641494-314FDE24-C56B-4082-B22A-85BF7341E09FQ35999625-D5AEAF74-4DF3-4F6E-86B8-04D471F963E5Q36161290-F1218791-9B78-4308-A59A-5EBD49A6FA15Q36163982-CDCFFE33-DB3D-49C7-9867-FE2E10FAB4CDQ36228534-2E183658-FCB8-48E7-8295-D140DFA62231Q36314452-A7369FCB-49FC-41BE-88C4-4DBFDE546FF1Q37388707-BC89DC31-1942-4668-AB86-2141D1EFFD04Q37640172-F992FD48-170D-4DFF-B049-59611E9877E2Q37645161-29DC2D5C-B58E-44A1-AB60-5F930A696623Q37652133-F4F58C95-EAA1-4196-AA8E-C3912B6FEB19Q37735690-A363E785-045F-4F53-B148-E74472BBB0DCQ37844529-6A2FF853-721B-42B1-9360-A9B131BDF7ECQ37955066-E1286460-5834-439D-9FD9-FE01DA43AF56Q38806041-14C2B2A2-31A9-4B54-A076-1028CE4F70CBQ38930166-E2A35C32-BF90-4C04-B975-164E8ED4AC8AQ42206299-DB9C242F-5421-4932-9D7F-BB1AA8089A8EQ46704761-687975C0-A9C7-4C3A-B007-79A721F6C186Q48455124-B438DCC6-A938-4DD4-8F4D-886309D9453CQ50609335-53A772D0-3B3B-42E5-91A2-5B66E9BCD438Q58919755-FEA1F97F-AA95-4DEF-B22C-66072265CB7A
P2860
Interstitial lung disease in lung cancer: separating disease progression from treatment effects.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Interstitial lung disease in l ...... ession from treatment effects.
@ast
Interstitial lung disease in l ...... ession from treatment effects.
@en
type
label
Interstitial lung disease in l ...... ession from treatment effects.
@ast
Interstitial lung disease in l ...... ession from treatment effects.
@en
prefLabel
Interstitial lung disease in l ...... ession from treatment effects.
@ast
Interstitial lung disease in l ...... ession from treatment effects.
@en
P2093
P1433
P1476
Interstitial lung disease in l ...... ression from treatment effects
@en
P2093
Malcolm Ranson
Paul Hulse
Sarah Danson
P304
P356
10.2165/00002018-200528020-00002
P577
2005-01-01T00:00:00Z
P6179
1043042475